This new insight may lead to the discovery of vascular DDAH activity as potential therapeutic targets for the treatment of diabetic cardiovascular complications and development of some new medicines like PDTC for treatment of diabetes-induced impairment of endothelium-dependent vasodilatation and prevention of diabetic cardiovascular complications. This evidence concerns the gene DDAH1 and diabetes mellitus.